Build vs buy dilemma: economics of manufacturing cell-based therapies

Live30 webinars are 30-minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

The remarkable success enjoyed by cell-based therapies, particularly CAR T therapies, has propelled manufacturers and the financial sector to invest tremendous effort and capital in this space. This acceleration has led to major bottlenecks in manufacturing capacity and shortage of raw materials, both of which were exaggerated during the pandemic. The industry’s frenzied push to resolve these challenges have kept the build vs. buy conversation center stage.

The recent market downturn and its inevitable economic impact has re-ignited the build vs. buy debate. Many pharma and biotech companies are re-thinking their strategies, including the use of their capital to strengthen their pipeline assets rather than building out their own cell therapy manufacturing facilities.

Given these developments, it is vital that cell therapy developers and their investors revisit the build vs buy strategy, assess the pros and cons, and design new models to make these life-changing therapies a reality.

This webinar will showcase:

• Key considerations related to the build vs buy decision for cell therapy manufacturing 
• Flexible and sustainable design strategies and best practices 
• Contingency planning based on current market conditions and exit strategies

Nirupama (Rupa) Pike

Senior Director of Technical Affairs , Advanced Therapies, Thermo Fisher Scientific

Rupa is the Sr. Director of Technical Affairs for Advanced Therapies at Thermo Fisher Scientific. The Office of Technical Affairs comprises scientific experts that serve as a strategic, innovational and educational leaders in the area of cell-based therapies, plasmids and mRNA therapeutics. In her prior role as the Director of Enterprise Science and Innovation Partnerships, she developed and managed strategic partnerships with global BioPharma, Biotech and Healthcare customers in the area of  Cell and Gene Therapy. Prior to this, she was the Head of Technical Operations (Patheon/Thermo Fisher Scientific) where she worked closely with customers to conduct technology transfer and process optimization activities related to GMP manufacturing of cell-based therapies. She has over 15 years of expertise in GMP manufacturing and has successfully led GMP operations, Process Development and MSAT activities, infrastructure buildout, customer relations and business development. In her past roles, she has been the Director of Cell Manufacturing for Program for Advanced Cell Therapy- UW Hospitals and Clinics. At Ligand Pharmaceuticals, she was part of the team that designed novel hematopoietic screening assays for erythropoietin and thrombopoietin in partnership with GlaxoSmithKline, a part of the program that led to development of Promacta®.

Watch now

SPEAKERS

Nirupama (Rupa) Pike

Senior Director of Technical Affairs , Advanced Therapies, Thermo Fisher Scientific

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 70

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 41

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 35

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 34

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 33

Days

Register